Lowering doses of cancer drugs could slash global health spending by $30B, new research shows

Studies suggest reducing doses of cancer drugs like Keytruda could save $30 billion annually and improve patient access. Merck changed Keytruda's dosage from weight-based to fixed, but research indicates lower doses may be equally effective, while Merck disputes these findings. The U.S. Department of Health and Human Services supports de-escalating treatments if evidence confirms safety and efficacy.